ACHE and dementia: Accordingly, the clinical neuroprotective application of AChE inhibitors has been proposed for neurological disorder diseases, including Alzheimer’s disease, senile dementia, ataxia, Parkinson’s disease, and myasthenia gravis, based on its effect on the beta-amyloid metabolism [17,18].